Therefore, multiple interventions, including nutritional support, physical exercise, and drug intervention such as Anamorelin (ONO‐7643) an high‐affinity, selective agonist of the ghrelin receptor which could significantly increased LBM and improved anorexia symptoms and the nutritional state are essential for the treatment of the loss of muscle mass or strength and sarcopenia (Aversa et al., 2017). Here, GHSR is linked to sarcopenia.